| Name | Title | Contact Details |
|---|
Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity.
Okogen serves the needs of adults and children with ocular infections by developing therapies to reduce suffering, improve quality of life, and preserve vision.
The Valens Company (TSX:VLNS) (OTCQX:VLNCF) is a multi-licensed, vertically-integrated cannabis company focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and white-label product development. The Valens Company is the largest third-party extraction Company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant. Additionally, our subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science.
We specialize in recruiting clinical research talent and understand the hiring objectives of our Medical Device, Biotechnology, and Pharmaceutical clients.
We are a clinical-stage drug discovery and development company advancing innovative therapies to significantly advance the current standard of treatment for serious unmet medical needs.